A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians

Background. A safe, affordable, and highly immunogenic meningococcal A conjugate vaccine (PsA-TT, MenAfriVac) was developed to control epidemic group A meningitis in Africa. Documentation of the safety specifications of the PsA-TT vaccine was warranted, with sufficient exposure to detect potential r...

Descripción completa

Detalles Bibliográficos
Autores principales: Tapia, Milagritos D., Sow, Samba O., Haidara, Fadima Cheick, Diallo, Fatoumata, Doumbia, Moussa, Enwere, Godwin C., Paranjape, Gandhali, Hervé, Jacques, Bouma, Enricke, Parulekar, Varsha, Martellet, Lionel, Chaumont, Julie, Plikaytis, Brian D., Tang, Yuxiao, Kulkarni, Prasad S., Hartmann, Katharina, Preziosi, Marie-Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639507/
https://www.ncbi.nlm.nih.gov/pubmed/26553682
http://dx.doi.org/10.1093/cid/civ626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4639507/
https://www.ncbi.nlm.nih.gov/pubmed/26553682
http://dx.doi.org/10.1093/cid/civ626

Ejemplares similares